Cinclus Pharma Holding AB (publ) (STO:CINPHA)
Sweden · Delayed Price · Currency is SEK 12.62
+0.20 (1.61%)
At close: Sep 4, 2026
Cinclus Pharma Holding AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 35.18 | 57.47 | 4.58 | 5.96 | 10.57 | - | |
Revenue Growth | -9.04% | 1154.80% | -23.14% | -43.63% | - | - |
Gross Profit | 35.18 | 57.47 | 4.58 | 5.96 | 10.57 | - |
Selling, General & Admin | 42.31 | 57.25 | 36.85 | 39.56 | 64.12 | 14.45 |
Research & Development | 283.19 | 198.4 | 136.66 | 166.68 | 157.18 | 69.82 |
Operating Expenses | 325.82 | 255.65 | 173.51 | 206.24 | 221.3 | 84.27 |
Operating Income | -290.64 | -198.18 | -168.93 | -200.28 | -210.73 | -84.27 |
Interest Expense | -0.4 | -0.4 | -8.73 | -7.45 | -0.08 | -0.01 |
Interest & Investment Income | 18.48 | 11.62 | 11.21 | 3.03 | 1.18 | - |
Currency Exchange Gain (Loss) | 3.24 | 3.24 | -2.08 | -10.49 | -21.39 | 8.01 |
Other Non Operating Income (Expenses) | 0 | 0 | 1.24 | 0.58 | 0 | 0 |
Pretax Income | -269.31 | -183.71 | -167.28 | -214.61 | -231.01 | -76.27 |
Income Tax Expense | 0.07 | 0.26 | 0.75 | 0.51 | 18.06 | - |
Net Income | -269.38 | -183.97 | -168.03 | -215.12 | -249.07 | -76.27 |
Net Income to Common | -269.38 | -183.97 | -168.03 | -215.12 | -249.07 | -76.27 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 51 | 47 | 37 | 26 | 23 | 21 |
Shares Outstanding (Diluted) | 51 | 47 | 37 | 26 | 23 | 21 |
Shares Change | 22.55% | 25.69% | 41.26% | 13.81% | 9.26% | 8415.70% |
EPS (Basic) | -5.25 | -3.95 | -4.54 | -8.20 | -10.81 | -3.62 |
EPS (Diluted) | -5.25 | -3.95 | -4.54 | -8.20 | -10.81 | -3.62 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -279.79 | -75.78 | -178.37 | -209.19 | -192.08 | -75.48 |
Free Cash Flow Per Share | -5.46 | -1.63 | -4.81 | -7.98 | -8.34 | -3.58 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | - |
Operating Margin | -826.22% | -344.84% | -3688.45% | -3360.98% | -1993.45% | - |
Profit Margin | -765.78% | -320.12% | -3668.80% | -3609.97% | -2356.20% | - |
Free Cash Flow Margin | -795.37% | -131.86% | -3894.48% | -3510.42% | -1817.01% | - |
EBITDA | -289.57 | -198.05 | -168.9 | -200.25 | -210.69 | -84.26 |
D&A For EBITDA | 1.07 | 0.13 | 0.03 | 0.03 | 0.04 | 0.01 |
EBIT | -290.64 | -198.18 | -168.93 | -200.28 | -210.73 | -84.27 |